JMT206
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 10, 2025
CSPC Pharmaceutical has received approval from the U.S. Food and Drug Administration to conduct clinical trials for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody JMT206 in the United States, according to a filing with the Hong Kong Stock Exchange.
(Investing.com)
IND • Obesity
November 26, 2025
CSPC Pharmaceutical’s JMT206 Receives Clinical Trial Approval in China
(TipRanks)
New trial • Obesity
1 to 2
Of
2
Go to page
1